GET DAILY SIGNALSSilo Pharma (SILO): Watching the Path Toward a +210% Move to the $5.70 Technical Level
Key Takeaways
- The $5.70 level is a technical resistance point noted in public commentary, not an analyst consensus price target, used here because SILO has limited current sell-side coverage.
- With shares recently near $1.84, reaching $5.70 would imply a gain of roughly 210%, a substantial move even for a volatile micro-cap.
- Only one stale analyst target exists ($150 from November 2023), plus a "Sell" rating from Weiss Ratings (August 2026); no meaningful current consensus is available.
- Potential supports include U.S., Canadian, and European patent allowances for SPC-15, expansion at the QwikAgents AI subsidiary, and a $1 million share buyback program.
- Major risks center on minimal revenue, ongoing net losses, dilution from equity and warrant issuances, and a weak technical trend.
How the $5.70 Technical Target Emerged
Silo Pharma, Inc. (SILO) carries very limited institutional analyst coverage. The sole identifiable equity analyst target sits at $150 and dates back to November 21, 2023, well removed from the current price. Weiss Ratings issued a "Sell" rating in August 2026, yet that reflects a ratings service rather than a traditional sell-side estimate. With no cluster of fresh analyst targets to average, the $5.70 figure comes instead from publicly discussed technical research. Investtech flagged resistance near $5.70, and MarketScreener shows a comparable zone around $5.76. This remains a technical milestone under observation, not a formal forecast.
Where the Stock Stands Today and the Scale of the Move
As of the most recent verified close, SILO traded near $1.84, toward the lower end of its 52-week range between roughly $1.10 and over $10. Closing the gap to $5.70 would require upside of about 210%. The stock has a history of sharp reactions to clinical and corporate news, so any advance would likely depend on discrete catalysts rather than gradual fundamental improvement. With a market capitalization of only a few million dollars and thin liquidity, sentiment shifts can drive outsized moves in either direction.
Factors That Could Support Progress
Pipeline developments offer the clearest potential catalysts. The lead program, SPC-15, targets PTSD and stress-induced anxiety via an intranasal route. The company has secured a U.S. Patent and Trademark Office notice of allowance, a Canadian notice of allowance, and a European patent grant. Plans to file an investigational new drug application for a Phase 1 trial remain in view. Separately, the QwikAgents subsidiary has broadened its AI agent platform, now including support for NVIDIA (NVDA) models, while a $1 million share repurchase authorization signals management alignment. These elements could lift sentiment, though none has yet generated meaningful revenue.
Obstacles That Could Limit Upside
Risks remain material. Silo Pharma operates at the developmental stage, posting annual revenue in the tens of thousands and persistent net losses of roughly $4.2 million in 2025, along with negative EBITDA. Operations have been funded repeatedly through equity and warrant issuances, including a November 2026 private placement expected to deliver about $815,000 in net proceeds, which adds dilution pressure. As a pre-revenue biotech, clinical setbacks, regulatory delays, or additional financing needs could weigh on the shares. The weak technical trend and absence of clear chart support introduce further downside considerations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key Technical Levels to Watch
On the downside, Investtech commentary has noted no clearly defined support in the recent chart, with further declines indicated. On the upside, the primary resistance zone lies around $5.70 to $5.76, aligning with the Investtech observation and the MarketScreener reading. Barchart data has similarly highlighted the $5.70 area as a stall point near prior moving-average levels. In short, $5.70 stands as a meaningful overhead barrier that would need to be cleared decisively before any broader recovery could be considered.
What to Monitor Going Forward
Because $5.70 is a technical objective rather than an analyst target, it carries no fixed 12-month horizon. I’m watching the IND submission and any FDA feedback for SPC-15, updates on SP-26 for fibromyalgia and chronic pain, additional patent news, quarterly cash burn and financing moves, and any adjustments to the buyback program. Continued equity raises and warrant exercises also merit attention, as they can materially affect share count and price.
Monitoring SILO with Tickeron AI Tools
I rely on Tickeron’s AI Daily Buy/Sell Signals to stay on top of names like this. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from shifting market conditions, technical behavior, and automated analysis. For a volatile, low-liquidity stock such as SILO, these signals help surface trend changes and position updates more efficiently than manual review alone. From what I see, the tool offers a practical way to track momentum across similar micro-caps without replacing independent judgment.
Final Assessment
Can SILO reach $5.70? The level represents a genuine, publicly cited technical resistance point rather than an analyst price target, and it sits roughly 210% above the recent price. The strongest supporting elements are SPC-15 patent progress, growth at the AI subsidiary, and the modest buyback, while the main hurdles remain minimal revenue, persistent losses, ongoing dilution, and a weak technical structure. With essentially no current sell-side coverage, the outcome will likely hinge on clinical and financing catalysts rather than consensus estimates. Investors should treat $5.70 as a technical milestone to monitor, not as a forecast or a guarantee.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for SILO shows an upward move is likely
SILO's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 86 similar instances where the Aroon Indicator showed a similar pattern. In 75 of the 86 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SILO as a result. In 86 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
SILO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SILO advanced for three days, in 213 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SILO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SILO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. SILO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.466) is normal, around the industry mean (3.498). P/E Ratio (-0.348) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (3.910) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (28.736) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SILO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology